Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AORT stock price vs NDSN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NDSN's multiple
Needs NDSN P/E.
Implied fair value · at AORT's multiple
Needs AORT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ARTIVION, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NORDSON CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
AORT vs ABT
Merck & Co., Inc.
AORT vs MRK
BOSTON SCIENTIFIC CORP
AORT vs BSX
JOHNSON & JOHNSON
AORT vs JNJ
ZIMMER BIOMET HOLDINGS, INC.
AORT vs ZBH
TELEFLEX INC
AORT vs TFX
ILLINOIS TOOL WORKS INC
AORT vs ITW
Hillenbrand, Inc.
AORT vs HI
DOVER Corp
AORT vs DOV
ITT INC.
AORT vs ITT
Parker-Hannifin Corp
AORT vs PH
IDEX CORP /DE/
AORT vs IEX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AORT can sustain 13.6% revenue growth while materially improving operating margin and ROIC, then AORT looks like a hold or selective buy because the current discount is likely reflecting quality differences rather than pure multiple compression.
On a P/E basis, AORT appears deeply undervalued versus NDSN, with an implied price of $7.65 versus the current $27.12, or -71.8% downside. However, the valuation picture is less extreme on revenue and EBITDA multiples, and AORT’s own historical range suggests the stock is trading above its longer-term band rather than at distressed levels.
Supporting Metrics
